Mineralys Therapeutics, Inc. MLYS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s retained earnings?
- Mineralys Therapeutics, Inc. (MLYS) reported retained earnings of -$496.51M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s retained earnings changed year-over-year?
- Mineralys Therapeutics, Inc.'s retained earnings decreased by 44.0% year-over-year, from -$344.73M to -$496.51M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s retained earnings?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s retained earnings has grown at a 105.3% compound annual growth rate (CAGR), from -$52.81M to -$457.17M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.